Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744256 | 0.83 | CTSL (0.72) | ALDH1A1CTSLCTSSCTSBTSHR | |
| SCHEMBL6744264 | 0.83 | CTSL (0.72) | ALDH1A1CTSLCTSSCTSBTSHR | |
| SCHEMBL7659537 | 0.83 | CYP2C19 (0.51) | ALDH1A1CTSLPOLBNPSR1CTSS | |
| SCHEMBL5518402 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CTSLPOLBNPSR1CTSS | |
| SCHEMBL6744250 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CTSLPOLBNPSR1GLA | |
| SCHEMBL6742147 | 0.82 | CTSS (0.51) | CTSLCTSSCTSB | |
| SCHEMBL5530337 | 0.80 | CTSS (0.56) | ALDH1A1CTSLPOLBNPSR1CTSS | |
| SCHEMBL6742702 | 0.78 | CTSS (0.43) | CTSLCTSSCTSB | |
| SCHEMBL6061195 | 0.77 | CTSS (0.68) | CTSLCTSSCTSB | |
| SCHEMBL6742158 | 0.77 | CTSS (0.68) | CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | ALDH1A1 4044/4885CTSL 10/4885POLB 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.